<DOC>
	<DOCNO>NCT01669083</DOCNO>
	<brief_summary>GSK557296 study woman indication enhance embryo blastocyst implantation woman undergo IVF treatment . This study first dose experience compound woman . It important characterize pharmacokinetics GSK557296 woman determine appropriate dos dose regimen future clinical study . Understanding pharmacokinetics GSK557296 woman also enable accurate characterization exposure-response relationship future study . Two previous study GSK557296 conduct men oral dos range 10 milligram ( mg ) 200 mg. GSK557296 study woman indication enhance embryo blastocyst implantation woman undergo IVF treatment . This bridging study characterize pharmacokinetics GSK557296 woman determine appropriate dos dose regimen future clinical study . This non-randomized , open label , adaptive design study healthy female volunteer . A maximum total 48 subject , participate different cohort . Subjects Cohort 1 receive 10 mg single dose follow repeat dose . A one week break occur allow analysis PK data , prior start second Cohort . Subjects Cohort 2 receive 150 mg single dose follow repeat dose . Cohort 3 Cohort 4 adaptive base requirement additional dos study PK data analyze first 2 cohort .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics , Safety Tolerability GSK557296 Healthy Women Volunteers After Single Repeat Dosing</brief_title>
	<detailed_description />
	<mesh_term>Diketopiperazines</mesh_term>
	<criteria>Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin &lt; =1.5xupper limit normal ( ULN ) Single QTcF &lt; 450 millisecond ( msec ) ; QTc &lt; 480 msec subject Bundle Branch Block Healthy determine responsible experienced physician Female 18 45 year age inclusive , time signing inform consent A female subject eligible participate Childbearing potential abstinent agree use contraception method sufficiently minimize risk pregnancy study . Body weight &gt; = 50 kilogram ( kg ) Body Mass Index ( BMI ) within range 19 29.9 kg per meter^2 ( inclusive ) A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result screen within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) A positive prestudy drug alcohol screen A positive test HIV antibody History regular alcohol consumption within 6 month study The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) , exposure four new chemical entity within 12 month prior first dose day Unable refrain use prescription nonprescription drug , exception Oral contraceptive , within 7 day 5 halflives ( whichever longer ) prior first dose study medication history sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation Where participation study would result donation blood blood product excess 500 milliliter ( mL ) within 56 day period Pregnant females Lactating female Unwillingness inability follow procedure outline protocol Subject mentally legally incapacitated Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen Unable refrain consumption red wine , seville orange , grapefruit grapefruit juice and/or pomelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Oxytocin Antagonist</keyword>
	<keyword>Embryo/Blastocyst Implantation</keyword>
</DOC>